Warner Chilcott Targets Ranbaxy’s Osteoporosis Generic

Law360, New York (April 27, 2012, 4:02 PM EDT) -- Warner Chilcott Co. LLC on Thursday redoubled its efforts to protect its osteoporosis drug Atelvia, launching a new infringement suit accusing Ranbaxy Laboratories Ltd. of violating its patents by developing a generic version of the drug.

Warner Chilcott said in New Jersey federal court that Ranbaxy's planned launch of a competing generic version of the oral tablets used to fight osteoporosis in postmenopausal women constitutes infringement of a pair of the company's drug patents.

Ranbaxy has “committed, aided, abetted, actively induced, contributed to or participated in...
To view the full article, register now.